Findings

What do systematic reviews say?

311 questions · 323 findings · 30 reviews

Sort:Best matchNewest Highest certainty Download CSV

No studies found 47 · 14.6%GRADE not reported 21 · 6.5%Very low 91 · 28.2%Low 65 · 20.1%Moderate 82 · 25.4%High 17 · 5.3%

Intervention not reported

True positivespeople with ethionamide resistance · adults with pulmonary tuberculosis with known rifampicin resistance, detected as tuberculosis positive by Xpert MTB/XDRRole: an initial…

1 finding from 1 review

Xpert MTB/XDR for detection of pulmonary tuberculosis and resistance to isoniazid, fluoroquinolones, ethionamide, and… 2022 · Cochrane Headline outcomes only
no estimate extracted
1 study · 167 participants
Very low

Intervention not reported

False negativespeople incorrectly classified as not having ethionamide resistance · adults with pulmonary tuberculosis with known rifampicin resistance, detected as tuberculosis positive by Xpert MTB/XDRRole: an initial…

1 finding from 1 review

Xpert MTB/XDR for detection of pulmonary tuberculosis and resistance to isoniazid, fluoroquinolones, ethionamide, and… 2022 · Cochrane Headline outcomes only
no estimate extracted
1 study · 167 participants
Very low

Intervention not reported

True negativespeople without ethionamide resistance · adults with pulmonary tuberculosis with known rifampicin resistance, detected as tuberculosis positive by Xpert MTB/XDRRole: an initial…

1 finding from 1 review

Xpert MTB/XDR for detection of pulmonary tuberculosis and resistance to isoniazid, fluoroquinolones, ethionamide, and… 2022 · Cochrane Headline outcomes only
no estimate extracted
1 study · 267 participants
Very low

Intervention not reported

False positivespeople incorrectly classified as having ethionamide resistance · adults with pulmonary tuberculosis with known rifampicin resistance, detected as tuberculosis positive by Xpert MTB/XDRRole: an initial…

1 finding from 1 review

Xpert MTB/XDR for detection of pulmonary tuberculosis and resistance to isoniazid, fluoroquinolones, ethionamide, and… 2022 · Cochrane Headline outcomes only
no estimate extracted
1 study · 267 participants
Very low

Intervention not reported

Test result · adults with pulmonary tuberculosis with known rifampicin resistance, detected as tuberculosis‐positive by Xpert MTB/XDR Index test: Xpert…

The review found no eligible studies for this question.

1 finding from 1 review

Xpert MTB/XDR for detection of pulmonary tuberculosis and resistance to isoniazid, fluoroquinolones, ethionamide, and… 2022 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Intervention not reported

True positivespeople with amikacin resistance · adults with pulmonary tuberculosis with known rifampicin resistance, detected as tuberculosis‐positive by Xpert MTB/XDR Index test: Xpert…

1 finding from 1 review

Xpert MTB/XDR for detection of pulmonary tuberculosis and resistance to isoniazid, fluoroquinolones, ethionamide, and… 2022 · Cochrane Headline outcomes only
no estimate extracted
1 study · 65 participants
Low

Intervention not reported

False negativespeople incorrectly classified as not having amikacin resistance · adults with pulmonary tuberculosis with known rifampicin resistance, detected as tuberculosis‐positive by Xpert MTB/XDR Index test: Xpert…

1 finding from 1 review

Xpert MTB/XDR for detection of pulmonary tuberculosis and resistance to isoniazid, fluoroquinolones, ethionamide, and… 2022 · Cochrane Headline outcomes only
no estimate extracted
1 study · 65 participants
Low

Intervention not reported

True negativespeople without amikacin resistance · adults with pulmonary tuberculosis with known rifampicin resistance, detected as tuberculosis‐positive by Xpert MTB/XDR Index test: Xpert…

1 finding from 1 review

Xpert MTB/XDR for detection of pulmonary tuberculosis and resistance to isoniazid, fluoroquinolones, ethionamide, and… 2022 · Cochrane Headline outcomes only
no estimate extracted
1 study · 425 participants
High

Intervention not reported

False positivespeople incorrectly classified as having amikacin resistance · adults with pulmonary tuberculosis with known rifampicin resistance, detected as tuberculosis‐positive by Xpert MTB/XDR Index test: Xpert…

1 finding from 1 review

Xpert MTB/XDR for detection of pulmonary tuberculosis and resistance to isoniazid, fluoroquinolones, ethionamide, and… 2022 · Cochrane Headline outcomes only
no estimate extracted
1 study · 425 participants
High

Intervention not reported

Test result · adults with pulmonary tuberculosis irrespective of rifampicin resistance (i.e. whether or not their rifampicin resistance status was…

The review found no eligible studies for this question.

1 finding from 1 review

Xpert MTB/XDR for detection of pulmonary tuberculosis and resistance to isoniazid, fluoroquinolones, ethionamide, and… 2022 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Intervention not reported

True positivespeople with isoniazid resistance · adults with pulmonary tuberculosis irrespective of rifampicin resistance (i.e. whether or not their rifampicin resistance status was…

1 finding from 1 review

Xpert MTB/XDR for detection of pulmonary tuberculosis and resistance to isoniazid, fluoroquinolones, ethionamide, and… 2022 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 756 participants
Moderate

Intervention not reported

False negativespeople incorrectly classified as not having isoniazid resistance · adults with pulmonary tuberculosis irrespective of rifampicin resistance (i.e. whether or not their rifampicin resistance status was…

1 finding from 1 review

Xpert MTB/XDR for detection of pulmonary tuberculosis and resistance to isoniazid, fluoroquinolones, ethionamide, and… 2022 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 756 participants
Moderate

Intervention not reported

True negativespeople without isoniazid resistance · adults with pulmonary tuberculosis irrespective of rifampicin resistance (i.e. whether or not their rifampicin resistance status was…

1 finding from 1 review

Xpert MTB/XDR for detection of pulmonary tuberculosis and resistance to isoniazid, fluoroquinolones, ethionamide, and… 2022 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 327 participants
Moderate

Selective serotonin reuptake inhibitors vs atypical agent

Improvement in depression at 6‐12 weeks: HAM‐D score (continuous) · adults living with HIV and depression

1 finding from 1 review

Antidepressants for depression in adults with HIV infection 2018 · Cochrane Headline outcomes only
no estimate extracted
1 study · 70 participants
Low

Selective serotonin reuptake inhibitors vs atypical agent

Improvement in depression at 6‐12 weeks: HAM‐D score (dichotomized) · adults living with HIV and depression

Selective serotonin reuptake inhibitor (SSRI) showed no clear difference in improvement in depression at 6‐12 weeks: HAM‐D score (dichotomized) compared with atypical agent (low certainty).

1 finding from 1 review

Antidepressants for depression in adults with HIV infection 2018 · Cochrane Headline outcomes only
RR 0.94 [0.79, 1.11]
1 study · 70 participants
Low

Selective serotonin reuptake inhibitors vs atypical agent

Improvement in depression at 6‐12 weeks: CGI‐I (score of 1 or 2) · adults living with HIV and depression

Selective serotonin reuptake inhibitor (SSRI) showed no clear difference in improvement in depression at 6‐12 weeks: CGI‐I (score of 1 or 2) compared with atypical agent (low certainty).

1 finding from 1 review

Antidepressants for depression in adults with HIV infection 2018 · Cochrane Headline outcomes only
RR 0.78 [0.52, 1.17]
1 study · 70 participants
Low

Selective serotonin reuptake inhibitors vs atypical agent

Dropout · adults living with HIV and depression

Selective serotonin reuptake inhibitor (SSRI) showed no clear difference in study dropouts at 6‐12 weeks compared with atypical agent (low certainty).

1 finding from 1 review

Antidepressants for depression in adults with HIV infection 2018 · Cochrane Headline outcomes only
RR 1.67 [0.43, 6.45]
1 study · 70 participants
Low

RISPERIDONE DEPOT vs ATYPICAL DEPOT ANTIPSYCHOTICS (PALIPERIDONE PALMITATE)

Relapse · patients with schizophrenia

1 finding from 1 review

Risperidone (depot) for schizophrenia 2016 · Cochrane Headline outcomes only
no estimate extracted
0 studies · 0 participants
GRADE not reported

RISPERIDONE DEPOT vs ATYPICAL DEPOT ANTIPSYCHOTICS (PALIPERIDONE PALMITATE)

Mental state: PANSS responders (ITT data) ‐ medium term PANSS responders‐ participants achieving a >30% improvement in total score · patients with schizophrenia

RISPERIDONE DEPOT showed no clear difference in mental state: PANSS responders (ITT data) ‐ medium term PANSS… compared with ATYPICAL DEPOT ANTIPSYCHOTICS (PALIPERIDONE PALMITATE) (moderate certainty).

1 finding from 1 review

Risperidone (depot) for schizophrenia 2016 · Cochrane Headline outcomes only
RR 1.01 [0.83, 1.23]
2 studies · 1326 participants
Moderate

RISPERIDONE DEPOT vs ATYPICAL DEPOT ANTIPSYCHOTICS (PALIPERIDONE PALMITATE)

Leaving the study early: lack of efficacy ‐ long term · patients with schizophrenia

RISPERIDONE DEPOT may leads to lower leaving the study early: lack of efficacy ‐ long term compared with ATYPICAL DEPOT ANTIPSYCHOTICS (PALIPERIDONE PALMITATE) (low certainty).

1 finding from 1 review

Risperidone (depot) for schizophrenia 2016 · Cochrane Headline outcomes only
RR 0.6 [0.45, 0.81]
1 study · 749 participants
Low